PRAME and cancer: Originally restricted to germline tissues, PRAME’s aberrant activation in somatic cells contributes to cancer development through multiple pathways, including suppression of retinoic acid (RA) signaling, induction of epithelial-to-mesenchymal transition (EMT), and modulation of the tumor immune microenvironment [26].